Last reviewed · How we verify
Dihydroartemisinin Piperaquine
Dihydroartemisinin Piperaquine is a Small molecule drug developed by Stanford University. It is currently FDA-approved. Also known as: DP, DP Placebo, Duo-cotecxin, Artekin, Duo-cotexcin.
At a glance
| Generic name | Dihydroartemisinin Piperaquine |
|---|---|
| Also known as | DP, DP Placebo, Duo-cotecxin, Artekin, Duo-cotexcin, Focal Mass Drug Administration |
| Sponsor | Stanford University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults (PHASE1)
- Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy (EARLY_PHASE1)
- Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria (PHASE4)
- Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana (NA)
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
- Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission (PHASE4)
- Perennial Malaria Chemoprevention in the Malaria Vaccine Era (PHASE4)
- Mass Vaccine and Drug Administration, Bangladesh (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dihydroartemisinin Piperaquine CI brief — competitive landscape report
- Dihydroartemisinin Piperaquine updates RSS · CI watch RSS
- Stanford University portfolio CI
Frequently asked questions about Dihydroartemisinin Piperaquine
What is Dihydroartemisinin Piperaquine?
Dihydroartemisinin Piperaquine is a Small molecule drug developed by Stanford University.
Who makes Dihydroartemisinin Piperaquine?
Dihydroartemisinin Piperaquine is developed and marketed by Stanford University (see full Stanford University pipeline at /company/stanford-university).
Is Dihydroartemisinin Piperaquine also known as anything else?
Dihydroartemisinin Piperaquine is also known as DP, DP Placebo, Duo-cotecxin, Artekin, Duo-cotexcin, Focal Mass Drug Administration.
What development phase is Dihydroartemisinin Piperaquine in?
Dihydroartemisinin Piperaquine is FDA-approved (marketed).
Related
- Manufacturer: Stanford University — full pipeline
- Also known as: DP, DP Placebo, Duo-cotecxin, Artekin, Duo-cotexcin, Focal Mass Drug Administration
- Compare: Dihydroartemisinin Piperaquine vs similar drugs
- Pricing: Dihydroartemisinin Piperaquine cost, discount & access